Immunofluorescent staining revealed that these anxiety-like behaviors were correlated with reduced vmPFC c-Fos expression, whereas EA treatment enhanced c-Fos levels in this region, consistent with functional vmPFC activation. The gene discussed is FOS; the disease is Anxiety.